Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors

This publication has 17 references indexed in Scilit:

• Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
  Journal of Clinical Oncology, 2001
• The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol Inhibits Glycogen Phosphorylase
  Archives of Biochemistry and Biophysics, 2001
• Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.
  International Journal of Oncology, 2000
• Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
  Journal of Biological Chemistry, 2000
• Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
  Journal of Clinical Oncology, 2000
• Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
  JNCI Journal of the National Cancer Institute, 1994
• Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
  Biochemical and Biophysical Research Communications, 1994
• Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activity
  Biochemical Pharmacology, 1993
• Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
  JNCI Journal of the National Cancer Institute, 1992
• An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis
  Tetrahedron, 1988